Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*
(Incorporated in Bermuda with limited liability)
(Stock Code: 00512)

VOLUNTARY ANNOUNCEMENT

JEXT® PRE-FILLED EPINEPHRINE AUTO-INJECTOR WAS GRANTED APPROVAL FOR GUANGDONG-HONG KONG-MACAO GREATER BAY AREA IMPORTED PHARMACEUTICALS FOR URGENT CLINICAL NEEDS IN MAINLAND CHINA

This announcement is made by the board of directors (the "**Board**") of Grand Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board is pleased to announce that the Group's Jext® pre-filled epinephrine auto-injector for the treatment of anaphylaxis has been granted approval by China Guangdong Province Medical Products Administration for Guangdong-Hong Kong-Macao Greater Bay Area Imported Pharmaceuticals for Urgent Clinical Needs in Mainland China. Accordingly, the product can be used in designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area ("**Greater Bay Area**"). The product being approved in Greater Bay Area fills up the market in Mainland China, and provides patients with a history of anaphylaxis an innovative and effective self-treatment method.

Anaphylaxis is a severe, life-threatening systemic allergic reaction and its main clinical feature is the rapid occurrence of life-threatening respiratory and circulatory system problems. "World Allergy Organization Anaphylaxis Guidance 2020" has mentioned that the global prevalence of anaphylaxis is between approximately 50 and 112 per 100,000 persons per year, and it keeps rising year by year, while the estimated lifetime prevalence is approximately 0.3%-5.1%. In some life-threatening cases of anaphylaxis, the patient's disease progression is extremely rapid, and the median time from the appearance of symptoms to anaphylaxis occurring is about 5-30 minutes. Therefore, promptly medical intervention is vital for the survival and benefit of patients. Guidelines or associations such as "World Allergy Organization Anaphylaxis Guidance 2020" , "Guideline for Emergency Management of Anaphylaxis 2019" , "American Academy of Allergy, Asthma & Immunology (AAAAI) , "European Academy of Allergy and Clinical Immunology ('**EAACI**')" clearly indicate that intramuscular epinephrine injection is currently recognized as the first-line treatment for anaphylaxis and it is recommended the

patients with a history of anaphylaxis need to reserve epinephrine auto-injector for early self-treatment.

As a first-line drug for the community treatment of anaphylaxis recommended by EAACI, the epinephrine auto-injector has obvious advantages such as rapid administration and low operational error rate compared with the other treatment methods. Compared with common syringes, using auto-injector can reduce the average time of administration by 70 seconds, and reduce administration errors. It is convenient and safe to use by oneself or by others when symptoms occur.

The Jext® pre-filled epinephrine auto-injector of the Group is a disposable auto-injector containing sterile epinephrine solution and it has been approved for commercialization in 21 countries and regions such as Spain, the United Kingdom, France, Germany and South Korea, etc., and has been launched worldwide for more than 10 years. Its safety and effectiveness have been fully verified. Jext® ensures patients safety while maintaining the operational convenience through a unique mechanical design. When urgent and life-threatening anaphylaxis caused by insect bites, food, drugs, or exercise occurs, patients can achieve self-treatment trough injecting single dose of epinephrine into the outside of the thigh muscle (intramuscular injection) and gain more valuable time to receive further systemic treatment. At present, the epinephrine injections are mainly in the form of ampoules in China and there are no epinephrine auto-injector products being commercialized. Patients still rely on the on-site treatment by medical staffs which greatly delays the golden window for patients with anaphylaxis. The approval of Jext® pre-filled epinephrine auto-injector in Greater Bay Area benefit patients in the Greater Bay Area with innovative product that urgently needed in clinical practice. It is of far-reaching significance for improving the survival probability and quality of life of patients.

Cerebro-cardiovascular emergency segment is one of the key directions of the Group's strategic plan in the field of pharmaceutical technology. As a "national essential drug production base", an "emergency medicines manufacturer for national ready reserve" and a "national centralized production base and construction unit for minority-variety medicines (drugs in short supply)", etc., the Group has with a total of 24 varieties in cerebro-cardiovascular emergency segment, 14 of which are included in the national emergency drugs catalogue covering 6 major categories, while 16 of which are included in the shortage drugs catalogue covering 6 major categories, which has ranked the top in the industry in terms of product pipeline. The Group's first generic product, epinephrine hydrochloride injection (pre-filled), was approved for commercialization in July 2022. The product has various features including convenient for operation, accurate medication, avoiding glass chips, and reducing secondary pollution. While optimizing the quality of the product, it can save valuable rescue time for the patients to a great extent. Currently, there are more than 20 products under research in the field of cerebro-cardiovascular emergency. Among which, the Jext® pre-filled epinephrine auto-injector can be used for self or family or social treatment for severe allergic reactions, which fills up the gap in China. The Group has made a systematic strategic plan in terms of epinephrine series products, providing various forms such as ampoules, pre-filled and auto-injector, which can meet the objective demands of different application scenarios. The approval of Jext® pre-filled epinephrine auto-injector in Guangdong-Hong Kong-Macao Greater Bay Area further accelerates the commercialization of the Group's high-barrier products in the field of emergency drugs, enhancing the competitiveness and professional authority of the Group in the field of emergency drugs, and laying a foundation for further commercialization of the product in

China. In the future, the Group will continue to focus on the three major emergency scenarios, namely in-hospital emergency, pre-hospital emergency and social emergency, and allocate and develop emergency products that are in urgent clinical need.

The Group always put a high value on the R&D of innovative products and advanced technologies. Sticking to patients-cantered and innovation-driven, the Group will continue to increase its investment in the world-class innovative products and advanced technologies to meet unmet clinical needs, and enrich product pipeline and improve supply chain. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. In this way, the Group can make full use of its industrial advantages and R&D capabilities, to accelerate commercialization process for innovative products and provide patients with more advanced and diverse treatment options in the world.

Warning：

The production, sales and corresponding profit of aforementioned product is subject to various factors such as market changes with uncertainty. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Grand Pharmaceutical Group Limited
Chairman
Dr. Tang Weikun

Hong Kong, 29 January 2023

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Dr. Shao Yan, Dr. Niu Zhanqi and Dr. Shi Lin, and three independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*